An Evolution of Drug Safety Assessment with Artificial Intel in Columbus, Ohio

For reporting and analyzing adverse events, pharmacovigilance has traditionally relied on manual processes, which frequently cause delays and potential errors. With its ability to process enormous amounts of data, identify patterns, and offer insights that are otherwise difficult to uncover, AI is quickly changing this environment.